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Two synthetic analogs of neplanocin A, which were shown in a separate study to be inhibitors of
S-adenosylhomocysteine hydrolase and devoid of substrate activity with adenosine kinase, were found in this
study to inhibit vaccinia virus replication in murine L929 cells but to have reduced cytotoxicity compared with
that of the parent compound. These results confirm that S-adenosylhomocysteine hydrolase is the molecular
target which mediates the antiviral effects of neplanocin A and that transformation by cellular adenosine kinase
mediates its cytotoxic properties.
S-Adenosylhomocysteine (AdoHcy) hydrolase (EC
3.3.1.1) has become an attractive target for the design of
antiviral agents (4). This cellular enzyme catalyzes the
hydrolysis of AdoHcy to adenosine and homocysteine, thus
maintaining low cellular concentrations of this product in-
hibitor of S-adenosylmethionine-dependent methylations
(11). Inhibition of cellular AdoHcy hydrolase, however,
results in intracellular accumulation of AdoHcy, a significant
increase in the intracellular AdoHcy/S-adenosylmethionine
ratio, and subsequent inhibition of S-adenosylmethionine-
dependent methylation reactions such as those essential for
viral mRNA maturation (e.g., 5'-methylated cap structure)
(2, 8, 10, 11). For example, our laboratory has reported that
neplanocin A is a potent inhibitor of cellular AdoHcy
hydrolase and an inhibitor of vaccinia virus replication in
murine L929 cells (2, 7). The antiviral action of neplanocin A
has been related to a decrease in viral mRNA methylation
and to a subsequent suppression of viral protein synthesis
(7). De Clercq and Cools (4) have also established a close
correlation between the antiviral potency of several adeno-
sine analogs, including neplanocin A, and their selective
inhibitory effects on AdoHcy hydrolase.
Neplanocin A is of interest as a prototype antiviral agent
because of its rather broad spectrum of antiviral effects (3),
but the therapeutic utility of neplanocin A as an antiviral
agent has been limited by its significant cytotoxicity (3, 12).
However, evidence does exist to suggest that the antiviral
effects of neplanocin A are mediated by its inhibition of
AdoHcy hydrolase (2, 3, 7), whereas, its cytotoxic effects
are mediated through its phosphorylation by adenosine
kinase and subsequent conversion of the neplanocin nucle-
otides to S-neplanocylmethionine (5, 6, 9).
Therefore, we have designed neplanocin A analogs [9-
(trans-2',trans-3'-dihydroxycyclopent-4'-enyl)-adenine (an-
alog 1) and -3-deazaadenine (analog 2) (Fig. 1)] that retain
inhibitory effects toward cellular AdoHcy hydrolase but are
devoid of substrate properties for cellular adenosine kinase
and adenosine deaminase. In this brief communication, we
have described the effects of neplanocin A and analogs 1 and












FIG. 1. Structures of neplanocin A (A) and analogs 1 and 2 (B).
In analog 1, X=N; in analog 2, X=CH.
The antiviral effects of neplanocin A and analogs 1 and 2
were determined in L929 mouse cells infected with vaccinia
virus. Experimental cultures for anti-vaccinia virus assays
were plated in multiculture plates with Waymouth MB 752/1
medium (Hazleton) containing 4% calf serum. Nearly
confluent cell monolayers were infected with vaccinia virus
at about 200 PFU per well. After a 60-min virus adsorption
period, the viral inoculum was diluted by the addition of
culture medium and then completely removed by aspiration.
Immediately after infection, each well containing a cell
monolayer was overlaid with medium containing 0.1%
methylcellulose to which was added medium containing test
compounds in serial dilutions in 0.5-log increments. After
incubation for 48 h at 37°C, cultures were washed with
phosphate-buffered saline and stained with 0.1% crystal
violet. The concentrations producing 50% inhibition of
TABLE 1. Antiviral activity and cytotoxicity of analogs 1
and 2 and of neplanocin A
Antiviral activity Cytotoxicity
and indexa and indexb Antiviral
Compound WmIC (test ID50 (test effectivenessIC50 corn Npon)! >M cmpound) (IDso/IC50)(~LM) copon)/4M)copudIC50 (NpcA)c /ID350 (NpcA)
1 0.28 3.5 17 34 61
2 0.95 11.9 56 112 59
NpcA 0.08 1 0.5 1 6
a Experiments conducted in duplicate.
b Experiments conducted in triplicate.
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FIG. 2. Cytocidal and cytostatic effects of neplanocin A and analogs 1 and 2 on murine L929 cells. L929 cells were cultured in the absence
of drug (O) or in the presence of drug at the following concentrations: *, 0.01 ,uM; A\, 0.1 ,uM; A, 1 ,uM; O, 10 FM; F-x, 32 ,uM; *, 100 ,uM.
(A) Compound 1; (B) compound 2; (C) neplanocin A. At the indicated times, the numbers of viable cells were determined as described in the
text.
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tion (IC50) and the antiviral indices (ratio of IC50 The effects of neplanocin A and analogs 1 and 2 on cell
compound/IC50 for neplanocin A) are summa- growth were determined by trypan blue staining of L929
)le 1. For comparative purposes, the IC50 for cells grown in various concentrations of the test compounds.
as determined in this assay to be 2.2 L929 cells were plated at 4.5 x 105cells per dish (30 mm) and
grown in Waymouth MB 752/1 medium containing 4% calf
serum. After a 6-h incubation, the cells were fed with fresh
medium with or without the test compounds. After incuba-
tion for 24, 48, or 72 h, the cells were dispersed by trypsin
treatment and suspended in phosphate-buffered saline con-
taining 0.04% trypan blue, and viable cells were counted
with a hemacytometer. The 50% cell growth inhibitor con-
centrations (ID5os) and the cell growth inhibitor indices (ratio
of ID50 for the test compound/ID50 for neplanocin A) are
summarized in Table 1. Cultures treated with concentrations
of analogs 1 and 2 as high as 100 ,uM produced only
cytostatic effects (Fig. 2). In contrast, concentrations of
neplanocin A as low as 32 1xM produced cytocidal effects.
The cytotoxic effects of the drugs were also assessed by
measuring their effects on DNA and RNA synthesis. Cul-
I,_ ,_,_,_ _ tures plated in 24-well dishes were incubated in modified0 oWoI 0.1 1 10 Waymouth medium containing 1% calf serum with or with-
-
out various concentrations of the test compounds at 37°C for
12 h and then pulse-labeled for 2 h with [methyl-3H]thymi-
dine or [5,6-3H]uridine. The radio-active culture medium
was removed by aspiration, and the monolayers were lysed
with solution containing 1% sodium dodecyl sulfate, 0.1
_
) \EDTA, 0.1 M Tris hydrochloride (pH 9.0), and 10 mM
vanadyl ribonucleoside complex (1). The lysate was trans-
Concentration of compound (pM)
FIG. 3. Effect of various concentrations of analogs 1 or 2 or of
neplanocin A on L929 cell DNA and RNA synthesis. L929 cells
were treated with various concentrations of analog 1 (0) or 2 (0) or
neplanocin A (A). Cultures were incubated at 37°C for 12 h and then
pulse-labeled with [methyl-3H]thymidine (final concentration, 0.5
i±Ci/ml) (A) or [5,6-3H]uridine (final concentration, 1.0 uCi/ml) (B)
for 2 h. The incorporation of radioactivity into RNA and DNA was
determined as described in the text.
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ferred onto a DE-81 disk. After being washed five times with
5% Na2HPO4 and two times with distilled water, each disk
was placed in a scintillation vial to which was added 10 ml of
3a70 scintillation cocktail, and the radioactivity remaining
on the disk was measured by liquid scintillation spectrom-
etry.
DNA synthesis as measured by incorporation of [methyl-
3H]thymidine was not inhibited by any of the test com-
pounds at concentrations of up to 10 ,uM (Fig. 3). RNA
synthesis as measured by incorporation of [5,6-3H]uridine
was unaffected by analogs 1 and 2 up to concentrations of 10
,M. However, treatment of cells with neplanocin A pro-
duced a concentration-dependent reduction in [5,6-3HJuri-
dine ihcorporation, indicating an inhibition of RNA synthe-
sis.
In separate studies, we have shown that analogs 1 and 2
are potent inhibitors of purified bovine liver AdoHcy
hydrolase (D. R. Borcherding, S. A. Scholtz, S. R. Naray-
anah, M. Hasobe, J. McKee, B. Keller, and R. T.
Borchardt, Fed. Proc. 46:860, 1987), and they inhibit
AdoHcy hydrolase in L929 cells, producing significant in-
creases in the intracellular ratio of AdoHcy/S-adenosyl-
methionine, but they are not metabolized by L929 cell
adenosine kinase or adenosine deaminase (M. Hasobe, J.
McKee, D. Borcherding, B. Keller, and R. T. Borchardt,
Fed. Proc. 46:93, 1987).
Thus, by removing the 4' hydroxymethyl group of neplano-
cin A, we have generated analogs that retain inhibitory
effects toward AdoHcy hydrolase and that have antiviral
effects. However, these analogs are devoid of substrate
activity toward adenosine kinase and thus have substantially
reduced cellular toxicity. These data suggest we have
achieved partial separation of the antiviral and cytotoxic
effects of neplanocin A. This separation of the antiviral and
cytotoxic effects can be illustrated by comparing the antivi-
ral effectiveness values (ID5d divided by IC50) for neplanocin
A and analogs 1 and 2, which are 6, 61, and 59, respectively.
The increased antiviral effectiveness of analogs 1 and 2
primarily reflects the reduction in cellular toxicity.
It is also interesting to note that compounds 1 and 2 do not
inhibit RNA synthesis at concentrations of up to 10 ,uM.
These results strongly suggest that inhibition of RNA syn-
thesis by neplanocin A is not related to the effect of the drug
on AdoHcy hydrolase, but instead results from its transfor-
mation to phosphorylated products or S-neplanocylmethio-
nine or both, as suggested by Glazer et al. (5, 6).
This work was supported by Public Health Service research grant
GM-29332 from the National Institutes of Health.
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